Palbociclib

IUPAC name

6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one

CAS No.

571190-30-2

Molecular Weight

447.5 g·mol−1

Molecular Formula

C24H29N7O2

Granule:    Available

Ready to press ‏o

Ready to fill þ

Palbociclib

Mechanism Of Action:

Palbociclib is a CDK4/6 inhibitor that acts by binding to the ATP pocket. The CDK4/6 kinase is involved in the G1-S transition, so, inhibition of this step prevents cell cycle in cells in whose this pathway is functioning.
 

Indication:

It is indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC), that has spread to other parts of the body; can be used in men and women.
HR+, HER2- is the most common subtype (approximately 60% of all cases) of metastatic breast cancer(mBC).